- Home
- RBCAA vs ARVN Comparison
RBCAA vs ARVN Comparison
Compare RBCAA & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBCAA
- ARVN
- Stock Information
- Founded
- RBCAA 1974
- ARVN 2015
- Country
- RBCAA United States
- ARVN United States
- Employees
- RBCAA N/A
- ARVN N/A
- Industry
- RBCAA Major Banks
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- RBCAA Finance
- ARVN Health Care
- Exchange
- RBCAA Nasdaq
- ARVN Nasdaq
- Market Cap
- RBCAA 1.3B
- ARVN 1.2B
- IPO Year
- RBCAA 1998
- ARVN 2018
- Fundamental
- Price
- RBCAA $63.82
- ARVN $7.02
- Analyst Decision
- RBCAA
- ARVN Buy
- Analyst Count
- RBCAA 0
- ARVN 13
- Target Price
- RBCAA N/A
- ARVN $34.42
- AVG Volume (30 Days)
- RBCAA 24.7K
- ARVN 3.5M
- Earning Date
- RBCAA 04-24-2025
- ARVN 05-06-2025
- Dividend Yield
- RBCAA 2.81%
- ARVN N/A
- EPS Growth
- RBCAA 12.83
- ARVN N/A
- EPS
- RBCAA 5.14
- ARVN N/A
- Revenue
- RBCAA $330,428,000.00
- ARVN $263,399,999.00
- Revenue This Year
- RBCAA $1.56
- ARVN N/A
- Revenue Next Year
- RBCAA $3.87
- ARVN $7.99
- P/E Ratio
- RBCAA $12.55
- ARVN N/A
- Revenue Growth
- RBCAA 6.29
- ARVN 235.54
- 52 Week Low
- RBCAA $46.81
- ARVN $6.88
- 52 Week High
- RBCAA $80.68
- ARVN $41.34
- Technical
- Relative Strength Index (RSI)
- RBCAA 43.37
- ARVN 23.50
- Support Level
- RBCAA $64.26
- ARVN $8.51
- Resistance Level
- RBCAA $66.15
- ARVN $9.17
- Average True Range (ATR)
- RBCAA 1.39
- ARVN 0.55
- MACD
- RBCAA 0.03
- ARVN -0.05
- Stochastic Oscillator
- RBCAA 20.56
- ARVN 5.24
About RBCAA Republic Bancorp Inc.
Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through six reportable segments. It has traditional banking which generates the majority of revenue, warehouse, mortgage banking, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans and receipt and payment of federal.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.